EntryPoint Capital LLC Sells 19,314 Shares of Harmony Biosciences Holdings, Inc. $HRMY

Key Points

• EntryPoint Capital LLC decreased its holdings in Harmony Biosciences by 60.2%, selling 19,314 shares, and currently owns 12,770 shares worth $424,000.
• Analyst ratings for Harmony Biosciences vary, with one strong buy, eight buys, and one hold, while the average price target is set at $51.00.
• In its latest earnings report, Harmony Biosciences missed consensus EPS estimates by earning $0.68 per share, with a revenue of $200.49 million, which was lower than the expected $204.37 million.

EntryPoint Capital LLC cut its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 60.2% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 12,770 shares of the company's stock after selling 19,314 shares during the period. EntryPoint Capital LLC's holdings in Harmony Biosciences were worth $424,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Financial Management Professionals Inc. acquired a new stake in Harmony Biosciences in the 1st quarter valued at $29,000. Brooklyn Investment Group boosted its stake in Harmony Biosciences by 1,031.9% in the 1st quarter. Brooklyn Investment Group now owns 1,064 shares of the company's stock valued at $35,000 after buying an additional 970 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in Harmony Biosciences in the 4th quarter valued at $41,000. Caitong International Asset Management Co. Ltd acquired a new stake in Harmony Biosciences in the 1st quarter valued at $57,000. Finally, CWM LLC boosted its stake in Harmony Biosciences by 34.8% in the 1st quarter. CWM LLC now owns 2,704 shares of the company's stock valued at $90,000 after buying an additional 698 shares in the last quarter. Institutional investors and hedge funds own 86.23% of the company's stock.

Analysts Set New Price Targets

Several analysts recently commented on HRMY shares. UBS Group decreased their price target on Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating on the stock in a research note on Monday, April 28th. Wall Street Zen lowered Harmony Biosciences from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th. Truist Financial started coverage on Harmony Biosciences in a research note on Monday, July 21st. They issued a "buy" rating and a $48.00 price target on the stock. Deutsche Bank Aktiengesellschaft reissued a "buy" rating and issued a $55.00 price objective (up previously from $54.00) on shares of Harmony Biosciences in a research note on Thursday, July 10th. Finally, Mizuho boosted their price objective on Harmony Biosciences from $44.00 to $48.00 and gave the stock an "outperform" rating in a research note on Thursday, May 15th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat.com, Harmony Biosciences presently has a consensus rating of "Buy" and an average price target of $51.00.

Harmony Biosciences Price Performance

Harmony Biosciences stock traded down $0.4730 on Monday, reaching $37.3870. The company's stock had a trading volume of 223,818 shares, compared to its average volume of 651,739. The company has a market cap of $2.15 billion, a price-to-earnings ratio of 12.07, a PEG ratio of 0.44 and a beta of 0.84. Harmony Biosciences Holdings, Inc. has a twelve month low of $26.47 and a twelve month high of $41.61. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.80 and a current ratio of 3.84. The business's fifty day moving average price is $34.47 and its 200 day moving average price is $33.62.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $0.68 earnings per share for the quarter, missing analysts' consensus estimates of $0.78 by ($0.10). The firm had revenue of $200.49 million for the quarter, compared to the consensus estimate of $204.37 million. Harmony Biosciences had a return on equity of 26.34% and a net margin of 23.44%.The company's revenue was up 16.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.05 EPS. Harmony Biosciences has set its FY 2025 guidance at EPS. Equities analysts expect that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current fiscal year.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.